Enanta Pharmaceuticals, Inc. (ENTA) Sets New 12-Month High at $38.46

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) hit a new 52-week high during trading on Tuesday . The stock traded as high as $38.46 and last traded at $38.53, with a volume of 147,190 shares traded. The stock had previously closed at $38.11.

Several equities research analysts recently commented on ENTA shares. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, June 27th. Robert W. Baird lifted their price target on shares of Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 8th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 11th. ValuEngine upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, J P Morgan Chase & Co restated an “overweight” rating and issued a $38.00 price objective (up from $32.00) on shares of Enanta Pharmaceuticals in a research note on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Enanta Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $36.00.

The firm’s market cap is $724.66 million. The company’s 50-day moving average price is $37.76 and its 200-day moving average price is $32.76.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The company had revenue of $7.51 million for the quarter, compared to analysts’ expectations of $8.08 million. Enanta Pharmaceuticals had a negative net margin of 51.85% and a negative return on equity of 7.74%. The firm’s revenue was down 46.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.06) earnings per share. Equities research analysts anticipate that Enanta Pharmaceuticals, Inc. will post $0.90 EPS for the current year.

Several hedge funds have recently modified their holdings of the company. TFS Capital LLC acquired a new position in shares of Enanta Pharmaceuticals during the first quarter valued at about $454,000. Ameriprise Financial Inc. raised its position in shares of Enanta Pharmaceuticals by 2.5% in the first quarter. Ameriprise Financial Inc. now owns 116,415 shares of the biotechnology company’s stock valued at $3,586,000 after buying an additional 2,880 shares in the last quarter. Swiss National Bank raised its position in shares of Enanta Pharmaceuticals by 5.4% in the first quarter. Swiss National Bank now owns 23,500 shares of the biotechnology company’s stock valued at $724,000 after buying an additional 1,200 shares in the last quarter. Comerica Bank raised its position in shares of Enanta Pharmaceuticals by 3.8% in the first quarter. Comerica Bank now owns 15,389 shares of the biotechnology company’s stock valued at $478,000 after buying an additional 558 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Enanta Pharmaceuticals by 2.6% in the first quarter. Bank of New York Mellon Corp now owns 199,078 shares of the biotechnology company’s stock valued at $6,132,000 after buying an additional 5,022 shares in the last quarter. 65.85% of the stock is currently owned by institutional investors.

WARNING: “Enanta Pharmaceuticals, Inc. (ENTA) Sets New 12-Month High at $38.46” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.com-unik.info/2017/08/19/enanta-pharmaceuticals-inc-enta-reaches-new-1-year-high-at-38-46-updated-updated.html.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

What are top analysts saying about Enanta Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit